Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 2/20 | 0.69 |
| ▸ | KIT | P10721 | 2/20 | 0.69 |
| ▸ | FLT1 | P17948 | 2/20 | 0.69 |
| ▸ | KDR | P35968 | 2/20 | 0.69 |
| ▸ | ABL2 | P42684 | 2/20 | 0.69 |
| ▸ | FLT4 | P35916 | 1/20 | 0.69 |
| ▸ | TERT | O14746 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30373903 | 1.00 | ADH1A (0.69) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL16487231 | 1.00 | ADH1A (0.69) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL4591116 | 0.87 | ADH1A (0.53) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL18100030 | 0.85 | ADH1A (0.51) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL28431476 | 0.85 | ADH1A (0.76) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL16486706 | 0.85 | ADH1A (0.76) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL16933054 | 0.85 | ADH1A (0.76) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL16847797 | 0.84 | ADH1A (0.50) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL14137732 | 0.84 | ADH1A (0.74) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL20975368 | 0.84 | ADH1A (0.74) | ADH1AKITFLT1KDRABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041134-A1 | Anti-HER2 Antibodies and Immunoconjugates | GENENTECH, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| EP-3782654-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | Genentech, Inc. (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3191135-B1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH INC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20200255539-A1 | Anti-HER2 Antibodies and Immunoconjugates | GENENTECH, INC. | 2020-08-13 | — | — | US | disclosed |
| US-10632210-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | GENENTECH, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10556966-B2 | Anti-HER2 antibodies and immunoconjugates | GENENTECH, INC. | 2020-02-11 | — | — | US | disclosed |
| US-10544215-B2 | 1-(Chloromethyl)-2,3-dihydro-1H-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment | GENENTECH, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10442836-B2 | 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment | GENENTECH, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190177429-A1 | Anti-HER2 Antibodies and Immunoconjugates | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-20190083643-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| WO-2016205176-A1 | ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| US-9518118-B2 | Anti-HER2 antibodies and immunoconjugates | GENENTECH, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160354485-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | GENENTECH, INC. (US) | 2016-12-08 | — | — | US | disclosed |
| EP-3082876-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | Genentech, Inc. (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-3033111-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | Genentech, Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| US-20160096893-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| WO-2016040723-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2015095212-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | GENENTECH, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150165063-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | AUCKLAND CANCER SOCIETY RESEARCH CENTRE (NZ) | 2015-06-18 | — | — | US | disclosed |
| WO-2015023355-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | GENENTECH, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150165063-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | IDO1, DBI, IDO2 | ADH1A 431/4885KIT 2127/4885FLT1 1438/4885 |
| US-10632210-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | DNPEP, LNPEP, BCR | ADH1A 4495/4885KIT 3497/4885FLT1 313/4885 |
| US-20190177429-A1 | Anti-HER2 Antibodies and Immunoconjugates | ERBB2, EGFR, ERBB3 | ADH1A 4622/4885KIT 467/4885FLT1 351/4885 |
| US-10556966-B2 | Anti-HER2 antibodies and immunoconjugates | ERBB2, EGFR, ERBB3 | ADH1A 4622/4885KIT 467/4885FLT1 351/4885 |
| US-20160096893-A1 | ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES | ERBB2, EGFR, ERBB3 | ADH1A 4622/4885KIT 467/4885FLT1 351/4885 |
| US-20200255539-A1 | Anti-HER2 Antibodies and Immunoconjugates | ERBB2, EGFR, ERBB3 | ADH1A 4622/4885KIT 467/4885FLT1 351/4885 |
| US-20190083643-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | DNPEP, LNPEP, BCR | ADH1A 4495/4885KIT 3497/4885FLT1 313/4885 |
| US-10442836-B2 | 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment | IDO1, DBI, IDO2 | ADH1A 431/4885KIT 2127/4885FLT1 1438/4885 |
| US-20160354485-A1 | 1-(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE DIMER ANTIBODY-DRUG CONJUGATE COMPOUNDS, AND METHODS OF USE AND TREATMENT | IDO1, DBI, IDO2 | ADH1A 431/4885KIT 2127/4885FLT1 1438/4885 |
| US-20230041134-A1 | Anti-HER2 Antibodies and Immunoconjugates | ERBB2, EGFR, ERBB3 | ADH1A 4622/4885KIT 467/4885FLT1 351/4885 |
| US-10544215-B2 | 1-(Chloromethyl)-2,3-dihydro-1H-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment | IDO1, DBI, IDO2 | ADH1A 431/4885KIT 2127/4885FLT1 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.